These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice. Sumitomo-Ueda Y; Aihara K; Ise T; Yoshida S; Ikeda Y; Uemoto R; Yagi S; Iwase T; Ishikawa K; Hirata Y; Akaike M; Sata M; Kato S; Matsumoto T Hypertension; 2010 Sep; 56(3):430-6. PubMed ID: 20660821 [TBL] [Abstract][Full Text] [Related]
24. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. Blinder MA; Tollefsen DM J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620 [TBL] [Abstract][Full Text] [Related]
25. Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Ise T; Aihara K; Sumitomo-Ueda Y; Yoshida S; Ikeda Y; Yagi S; Iwase T; Yamada H; Akaike M; Sata M; Matsumoto T Hypertens Res; 2011 Feb; 34(2):225-31. PubMed ID: 21107326 [TBL] [Abstract][Full Text] [Related]
26. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. Van Deerlin VM; Tollefsen DM J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083 [TBL] [Abstract][Full Text] [Related]
27. Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex. Verhamme IM Anal Biochem; 2012 Feb; 421(2):489-98. PubMed ID: 22206940 [TBL] [Abstract][Full Text] [Related]
28. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition. Ciaccia AV; Monroe DM; Church FC J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031 [TBL] [Abstract][Full Text] [Related]
29. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Takamori N; Azuma H; Kato M; Hashizume S; Aihara K; Akaike M; Tamura K; Matsumoto T Circulation; 2004 Feb; 109(4):481-6. PubMed ID: 14744972 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II. Han JH; Côté HC; Tollefsen DM J Biol Chem; 1997 Nov; 272(45):28660-5. PubMed ID: 9353333 [TBL] [Abstract][Full Text] [Related]
31. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Kondo S; Tokunaga F; Kario K; Matsuo T; Koide T Blood; 1996 Feb; 87(3):1006-12. PubMed ID: 8562924 [TBL] [Abstract][Full Text] [Related]
32. Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin. Sheffield WP; Blajchman MA FEBS Lett; 1995 May; 365(2-3):189-92. PubMed ID: 7781777 [TBL] [Abstract][Full Text] [Related]
33. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. Holland CA; Henry AT; Whinna HC; Church FC FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038 [TBL] [Abstract][Full Text] [Related]
34. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. Parker KA; Tollefsen DM J Biol Chem; 1985 Mar; 260(6):3501-5. PubMed ID: 3838315 [TBL] [Abstract][Full Text] [Related]
35. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Giri TK; Tollefsen DM Blood; 2006 Apr; 107(7):2753-8. PubMed ID: 16339402 [TBL] [Abstract][Full Text] [Related]
36. Structure-function relationships in heparin cofactor II: spectral analysis of aromatic residues and absence of a role for sulfhydryl groups in thrombin inhibition. Church FC; Meade JB; Pratt CW Arch Biochem Biophys; 1987 Dec; 259(2):331-40. PubMed ID: 3426230 [TBL] [Abstract][Full Text] [Related]
37. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II. Sutherland JS; Bhakta V; Sheffield WP Thromb Res; 2006; 117(4):447-61. PubMed ID: 15869786 [TBL] [Abstract][Full Text] [Related]
38. Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteins. Petzelbauer E; Seiffert D; Beckmann R; Pusch B; Geiger M; Binder BR Thromb Res; 1992 Jun; 66(5):559-67. PubMed ID: 1381850 [TBL] [Abstract][Full Text] [Related]
39. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition. Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357 [TBL] [Abstract][Full Text] [Related]
40. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition. Sutherland JS; Bhakta V; Filion ML; Sheffield WP Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]